Despite staffing cuts at CMS, Organogenesis expects to manage through the challenges. Click here to read why I rate ORGO ...

Rhumbline Advisers grew its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO – Free Report) by 7.1% during the 4th ...

Organogenesis has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.28, suggesting that its share price is ...

A negotiation for a tax stabilization agreement (TSA) between Smithfield and the biomedical company Organogenesis may be off to an unstable start, but the town and company seem ...

Welcome, ladies and gentlemen, to the fourth quarter and fiscal year 2024 earnings conference call for Organogenesis Holdings, Inc. At this time, all participants have been placed in listen-only mode.

Welcome, ladies and gentlemen to the fourth quarter and fiscal year 2024, earnings conference call for Organogenesis Holdings Inc. (Operator Instructions) Before we begin, I would like to remind ...

Learn more here. Operator Welcome, ladies and gentlemen, to the fourth quarter and fiscal year 2024 earnings conference call ...

Organogenesis Holdings Inc. (NASDAQ: NASDAQ:ORGO) reported a notable performance for the fourth quarter of 2024, exceeding analyst expectations with an earnings per share (EPS) of $0.04 against a ...

CANTON, Mass. (AP) — CANTON, Mass. (AP) — Organogenesis Holdings Inc. (ORGO) on Thursday reported profit of $7.7 million in its fourth quarter. On a per-share basis, the Canton, Massachusetts ...